Medpace Holdings
23 named things its latest annual report says its results depend on, each in the company's own words. 15 of them are also named by other companies we've read.
Customers
Top ten customers
concentrated in · approximately 35.1% of our net revenuenamed as a riskAlthough we did not have any customer that represented 10% or more of our net revenue during the year ended December 31, 2025, we derive approximately 35.1% of our net revenue from our top ten customers.Risk factors (Item 1A)
Also named by BGC, CBOE, CVLG, ENTG, FBIN, HUBB, LPX, MU and 9 more
Small biopharmaceutical companies
earns from · 82% of our net revenuenamed as a riskClinical trials can be costly and for the year ended December 31, 2025, 82% and 13% of our net revenue was derived from small biopharmaceutical companies and mid-sized biopharmaceutical companies, respectively, which may have limited access to capital.Risk factors (Item 1A)
Mid-sized biopharmaceutical companies
earns from · 13% of our net revenuenamed as a riskClinical trials can be costly and for the year ended December 31, 2025, 82% and 13% of our net revenue was derived from small biopharmaceutical companies and mid-sized biopharmaceutical companies, respectively, which may have limited access to capital.Risk factors (Item 1A)
Other companies
Medpace Investors LLC
approximately 19.0% of the outstanding sharesnamed as a riskAs of December 31, 2025, August J. Troendle, our Chief Executive Officer and founder, through his direct ownership of 646,184 shares of our common stock and his beneficial ownership of 4,733,019 shares of our common stock held by Medpace Investors LLC (“Medpace Investors”), controls approximately 19.0% of the outstanding shares of our common stock.Risk factors (Item 1A)
Competitors
IQVIA Holdings Inc.
competes withOur major CRO competitors include IQVIA Holdings Inc., ICON plc, PPD, Inc. (now part of Thermo Fisher Scientific Inc.), Fortrea, Inc., and numerous specialty and regional CROs.Business (Item 1)
Also named by VEEV
ICON plc
competes withOur major CRO competitors include IQVIA Holdings Inc., ICON plc, PPD, Inc. (now part of Thermo Fisher Scientific Inc.), Fortrea, Inc., and numerous specialty and regional CROs.Business (Item 1)
Also named by IQV
PPD, Inc. (Thermo Fisher Scientific Inc.)
competes withOur major CRO competitors include IQVIA Holdings Inc., ICON plc, PPD, Inc. (now part of Thermo Fisher Scientific Inc.), Fortrea, Inc., and numerous specialty and regional CROs.Business (Item 1)
Fortrea, Inc.
competes withOur major CRO competitors include IQVIA Holdings Inc., ICON plc, PPD, Inc. (now part of Thermo Fisher Scientific Inc.), Fortrea, Inc., and numerous specialty and regional CROs.Business (Item 1)
Places
China
subject tonamed as a risktariffs imposed by the U.S. government on certain imported goods, equipment, technology, or supplies used in our clinical trials, any retaliatory and/or reciprocal tariffs imposed on U.S. exports by foreign countries, including China, as well as any additional tariffs, duties, or other trade measures or restrictions could increase our operating costs, disrupt our global supply chain, lead to changes in the business environment in which we operate, or otherwise have a material adverse effect on our business, financial condition, or results of operations;Risk factors (Item 1A)
Also named by A, AA, AAOI, AAP, AAPL, AB, ADI, AEHR and 261 more
Cincinnati, Ohio
concentrated inOur Bioanalytical Laboratory is located on our clinical research campus in Cincinnati, Ohio.Business (Item 1)
Commodities and inputs
Euro
exposed to its price · approximately 91.1% and 82.8% of revenue denominated in foreign currencies and approximately 49.7% and 51.6% of operational costs denominated in foreign currencies were Euro denominatednamed as a riskOf these exposures, approximately 91.1% and 82.8% of revenue denominated in foreign currencies and approximately 49.7% and 51.6% of operational costs denominated in foreign currencies were Euro denominated for the years ended December 31, 2025 and 2024, respectively.Market risk (Item 7A)
Also named by ABBV, ABNB, ABT, ADBE, ADI, AME, AMG, AMGN and 186 more
Regulators
U.S. Food and Drug Administration (FDA)
subject tonamed as a riskFor example, we are subject to regulation by the FDA, and comparable foreign regulatory authorities relating to our activities in conducting pre-clinical studies and clinical trials.Risk factors (Item 1A)
Also named by A, ABBV, ABT, AMGN, ARE, ARWR, ATR, AXGN and 112 more
Drug Enforcement Administration (DEA)
subject tonamed as a riskWe are also subject to regulation by the Drug Enforcement Administration, or DEA, which regulates the distribution, recordkeeping, handling, security, and disposal of controlled substances.Risk factors (Item 1A)
Also named by CAH, COR, DGX, DHR, HALO, HSIC, IQV, LH and 7 more
Laws and programs
General Data Protection Regulation (GDPR)
subject to · up to 20 million EUR or up to 4% of the total worldwide annual turnovernamed as a riskIf we do not comply with our obligations under the GDPR we could be exposed to significant fines of up to 20 million EUR or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher.Risk factors (Item 1A)
Also named by A, AB, ABNB, ADBE, ADP, AGX, AIOT, AJG and 100 more
HIPAA
subject to · up to $1.5 million in annual civil penalties for each HIPAA violationnamed as a riskTwo of our subsidiaries, Medpace Clinical Pharmacology, LLC and C-MARC, LLC, are covered entities under HIPAA.Risk factors (Item 1A)
Also named by AFL, BAX, BBSI, CI, DHR, DOC, DOCN, DOCU and 19 more
Foreign Corrupt Practices Act (FCPA)
subject tonamed as a riskWe are required to comply with the FCPA, UK Bribery Act of 2010 and other U.S. and foreign anti-corruption laws, which prohibit companies from engaging in bribery including corruptly or improperly offering, promising, or providing money or anything else of value to foreign officials and certain other recipients.Risk factors (Item 1A)
Also named by A, ADBE, ADP, AIR, AJG, ALB, AME, AMZN and 112 more
Affordable Care Act
subject tonamed as a riskIf regulatory cost containment efforts limit the profitability of new drugs, our customers may reduce their R&D expenditures, which could reduce the business they outsource to us.Risk factors (Item 1A)
Also named by ABBV, ABT, ADP, AFL, BBSI, BRO, BWIN, COR and 8 more
Clinical Laboratory Improvement Amendments (CLIA)
subject tonamed as a riskThe sanction for failure to comply with CLIA requirements may be suspension, revocation or limitation of a laboratory’s CLIA certificate, which is necessary to conduct business, as well as significant fines and/or criminal penalties.Risk factors (Item 1A)
Good Clinical Practice (GCP)
subject tonamed as a riskMany of the functions we regularly perform in the conduct of clinical trials subject us directly to regulations (e.g., compliance with GCP), and in some circumstances, we will take on legal and regulatory responsibility either through a transfer of obligations to us from our clinical trial customers or our acting as local legal representative for certain of our clinical trial customers.Business (Item 1)
Also named by IQV
21 CFR Part 11
subject tonamed as a riskAny failures to comply with those regulatory requirements could impact our customers’ ability to rely on the data contained in those electronic records in our systems or result in the FDA’s rejection of the data.Risk factors (Item 1A)
Federal Food, Drug, and Cosmetic Act
subject toIn the United States, these trials must be conducted in accordance with the Federal Food, Drug, and Cosmetic Act, its implementing regulations, and other federal and state requirements that require the drug to be tested and studied in certain ways prior to approval.Business (Item 1)
Technology
ClinTrak
depends onnamed as a riskOur business depends on the continued effectiveness and availability of our information systems, including the information systems we use to provide our services to our customers, such as ClinTrak, and failures of these systems may materially limit our operations.Risk factors (Item 1A)